Abstract: The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or an ethylene glycol-containing moiety; and (ii) a ligand of the formula D-L1-Z-L2, wherein D comprises an antifolate drug or folic acid, L1 comprises a first linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, L2 comprises a second linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, wherein L1 and L2 may be the same or different, and wherein Z represents a carbonyl-containing group linking L1 and L2, and wherein L2 is coupled to said core. Also provided are pharmaceutical compositions comprising such nanoparticles, medical uses thereof and methods for producing the nanoparticles.

Abstract: The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or a polyethyleneglycol moiety; and (ii) a ligand of the formula MTX-L-, wherein MTX-L-represents methotrexate coupled to said core via a linker L. Also provided are pharmaceutical compositions of the nanoparticle, including gel formulations, and medical uses of the nanoparticle and pharmaceutical compositions, including for the treatment of an inflammatory or autoimmune disorder, such as psoriasis.

Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.

Abstract: The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: at least one liver-targeting ligand, such as C2-alpha galactose; at least one payload ligand comprising a bioactive agent, such as maytansinoid DM1; and at least one dilution ligand comprising a poly(ethyleneglycol) (PEG) moiety, such as PEG COOH. Also provided are pharmaceutical compositions comprising the nanoparticle, and uses of the nanoparticle in methods of treatment of liver disorders, including liver cancers such as hepatocellular carcinoma (HCC).

Abstract: The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: at least one liver-targeting ligand, such as C2-alpha galactose; at least one payload ligand comprising a bioactive agent, such as maytansinoid DM1; and at least one dilution ligand comprising a poly(ethyleneglycol) (PEG) moiety, such as PEG COOH. Also provided are pharmaceutical compositions comprising the nanoparticle, and uses of the nanoparticle in methods of treatment of liver disorders, including liver cancers such as hepatocellular carcinoma (HCC).

Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.

Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.

Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.

Abstract: A galley cart is suspended from a rail or track that extends along the length of an aircraft cabin above the aisle and rows of passenger seats of the aircraft. The galley cart is automated to move along the track above the aisle in response to movements of a flight attendant that is serving passengers from the suspended galley cart. The galley cart is provided with open bins for storage of food products, a beverage dispenser that is operable by the flight attendant to dispense a beverage requested by a passenger from a plurality of different beverages available from the suspended cart, and an ice dispenser for serving ice with the beverages requested by the passengers.

Abstract: A multi-section lid for a can containing edible material includes a lid base, a cover portion, and a tear strip. The lid base can attach the lid to the can. The lid base defines one or more openings that permit access to the edible material. The cover portion includes one or more doors to cover the openings. The tear strip portion is positioned between the lid base and the cover portion. The tear strip portion is connected to the lid base and the cover portion by a plurality of bridges. The mold for forming the lid includes cavities that define flow channels that permit the lid material to flow through bridge cavities to fill the cavities in the mold during formation of the lid such that the lid base, the cover portion, and the tear strip portion are the single integral component.

Abstract: A multi-section lid for a can containing edible material includes a lid base, a cover portion, and a tear strip. The lid base can attach the lid to the can. The lid base defines one or more openings that permit access to the edible material. The cover portion includes one or more doors to cover the openings. The tear strip portion is positioned between the lid base and the cover portion. The tear strip portion is connected to the lid base and the cover portion by a plurality of bridges. The mold for forming the lid includes cavities that define flow channels that permit the lid material to flow through bridge cavities to fill the cavities in the mold during formation of the lid such that the lid base, the cover portion, and the tear strip portion are the single integral component.

Abstract: The invention provides inhibitors of Wnt signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein R1 to R7 and Z are as defined herein.

Abstract: A multi-section lid for a can containing edible material includes a lid base, a cover portion, and a tear strip. The lid base can attach the lid to the can. The lid base defines one or more openings that permit access to the edible material. The cover portion includes one or more doors to cover the openings. The tear strip portion is positioned between the lid base and the cover portion. The tear strip portion is connected to the lid base and the cover portion by a plurality of bridges. The mold for forming the lid includes cavities that define flow channels that permit the lid material to flow through bridge cavities to fill the cavities in the mold during formation of the lid such that the lid base, the cover portion, and the tear strip portion are the single integral component.